Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib Window of Opportunity in Recurrent NMIBC
NCT03914794Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2020
- Primary completion
- Sep 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in non-muscle-invasive bladder cancer (NMIBC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Complete response rate of pemigatinib therapy at 6 weeks. Started Oct 2020; status: completed.
02
Drugs
pemigatinib
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03914794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03914794.